Good Lifestyle

Ozempic has become synonymous with weight loss drugs, but it is far from the only option. Although it can have the most recognizable name, Novo Nordisk's medication - a treatment of diabetes prescribed out of AMM for weight loss - is one of the many similar drugs. Ozempic's sister fired, Wegovy , is actually approved for weight loss, as is the new treatment of Eli Lilly, Zepbound. But now another competitor is fighting for a first place in the field of weight loss, and new data suggest that it could work even faster than its predecessors.

In relation: Big Ozempic Warning by Jillian Michaels: he makes you a "life prisoner".

The experimental drug of Viking Therapeutics VK2735 showed promising results in a recent mid-term test, according to a company on February 27 Press release . The test registered 176 obese adults (having a body mass index [BMI] of 30 or more) or overweight (having a BMI of 27 or more) with at least one comorbid condition linked to the weight. Patients received a dose of weekly VK2735 or placebo for 13 weeks.

During the 13 weeks, patients taking VK2735 lost up to 14.7% of their body weight (around 32 pounds) - which was 13% more than the Lost Placebo group, according to the press release.

According to Business Insider, while the semaglutide (Ozempic and Wegovy) and shooting tests (Zepbound and Mounjaro) had similar results, they also had longer clinical trials —Seaning VK2735 can operate even faster. Semaglutide tests took place 68 weeks, while the shooting tests lasted 16 months, Business Insider reported.

A "robust weight loss" was reported for all doses of VK2735 compared to the placebo group, and weight loss reductions were "progressive" throughout the study. Because patients did not put their weight loss at 13 weeks, "additional weight loss could be obtained from prolonged dosage periods", " Brian Lian , PhD, chief executive officer of Viking, said in the press release.

In relation: Ozempic patients say that "stops working" for weight loss - how to prevent this .

The new Viking medication is a peptide 1 glucagon 1 (GLP-1) and an insulinotropic polypeptide antagonist (GIP) dependent on glucose (GIP), which means that it targets two hormones. The shooting also targets two hormones, while the semaglutide only targets GLP-1. As doctors said to Business Insider in December 2023, targeting could make certain drugs more effective for weight loss.

In addition to being effective, VK2735 "has demonstrated encouraging security and tolerability," the press release said.

Twenty-three patients (13%) interrupted treatment, including five in the placebo cohort and 18 in the VK2735 treatment cohort. Among those who receive the experimental medication, 92% reported emerging adverse events (TEAES) and one reported a serious adverse (SAE) of dehydration event.

Most TEAA (95%) were light to moderate gastrointestinal side effects (GI), including nausea and vomiting. Viking's press release adds that these gastrointestinal side effects tended to occur early in treatment and decreased with repeated dosage. AE0FCC31AE342FD3A1346EBB1F342FCB

In a press release statement, Lian said that Viking was "excited" by the latest results and noted that the company was also working on a VK2735 pill form.

Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.